Analytic Investors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Analytic Investors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-16,429	Closed	-$1.46M	–	697
2015 Q4	$1.46M	Sell	16,429 -3,421	-17%	-$270K	0.02%	338
2015 Q3	$1.47M	Buy	+19,850	New	+$1.65M	0.02%	320

Other funds holding EGRX

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Analytic Investors's EGRX Position: Q1 2016 in Review

Analytic Investors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2016, closing a stake of 16,429 shares — an estimated $1.46M sold.

Analytic Investors first reported a position in EGRX in Q3 2015 and held it in 2 quarters. The position peaked at $1.47M in Q3 2015. 119 funds tracked by Wall St. Rank hold EGRX as of Q1 2016.

Analytic Investors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Analytic Investors sold 16,429 Eagle Pharmaceuticals, Inc. shares in Q1 2016, an estimated $1.46M.
Analytic Investors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
Analytic Investors's Eagle Pharmaceuticals, Inc. position peaked at $1.47M in Q3 2015.
119 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2016.

Based on Analytic Investors's 13F filing for Q1 2016, filed 20 May 2016.